Roth Capital starts Celsion at buy
Roth Capital Partners has initiated coverage of Celsion (NASDAQ:CLSN) with a “buy” rating and $10 price target, citing a “positive opinion” on the company’s on its core technology and late-stage lead...
View ArticleClik here to view.
CytRx posts positive preliminary data for aldoxorubicin
CytRx (NASDAQ:CYTR) has reported compelling preliminary data from its global Phase 2b soft tissue sarcoma trial, indicating that patients treated with aldoxorubicin had a significantly higher overall...
View ArticleClik here to view.
CytRx awaiting soft tissue sarcoma data in December
What if it were possible to deliver a broad range of potent cancer drugs more optimally, enhancing both their safety and efficacy? That’s the question CytRx (NASDAQ:CYTR) hopes to answer this December...
View ArticleClik here to view.
CytRx STS data to be featured at CTOS meeting
CytRx (NASDAQ:CYTR) said that additional preliminary data from its Phase 2b clinical trial, demonstrating aldoxorubicin’s potential advantage over doxorubicin in the treatment of soft tissue sarcoma...
View Article
